Format

Send to

Choose Destination
Pulm Pharmacol Ther. 2010 Aug;23(4):231-4. doi: 10.1016/j.pupt.2010.04.002. Epub 2010 Apr 7.

Doxofylline: a "novofylline".

Author information

1
Sackler Institute of Pulmonary Pharmacology, King's College London, 5th Floor, Franklin Wilkins Building, 150 Stamford Street, Waterloo Campus, London SE1 9NH, UK. clive.page@kcl.ac.uk

Abstract

Xanthines such as theophylline have been used in the treatment of lung diseases since the early 1900's, but have a major drawback of a very narrow therapeutic window and many drug/drug interactions. With the increasing availability of other classes of drugs, this has limited the use of xanthines. Doxofylline is a xanthine molecule that appears to be both bronchodilator and anti-inflammatory with an improved therapeutic window over conventional xanthines such as theophylline and the evidence supporting the effects of doxofylline in the treatment of lung diseases is discussed.

PMID:
20380886
DOI:
10.1016/j.pupt.2010.04.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center